Patents Assigned to Regeneron Pharmaceuticals, Inc.
-
Publication number: 20250129363Abstract: Cas-protein-ready tau biosensor cells, CRISPR/Cas synergistic activation mediator (SAM)-ready tau biosensor cells, and methods of making and using such cells to screen for genetic modifiers of tau seeding or aggregation are provided. Reagents and methods for sensitizing such cells to tau seeding activity or tau aggregation or for causing tau aggregation are also provided.Type: ApplicationFiled: December 17, 2024Publication date: April 24, 2025Applicant: Regeneron Pharmaceuticals, Inc.Inventors: Marine Prissette, Matthew Koss, Wen Fury, Brian Zambrowicz
-
Publication number: 20250127992Abstract: Disclosed herein are delivery devices for delivering a volume of a drug product, placebo product, or other product including a fluid. The devices may include a barrel having a longitudinal axis, a proximal end region, and a distal end region. The proximal end region may include an opening, and the barrel may be configured to receive a drug therein. A plunger rod may be disposed at least partially inside the barrel and protruding from the opening. The plunger rod may include a rack having a plurality of teeth. The device may further include a pinion having a plurality of teeth configured to engage with the plurality of teeth of the rack, and rotation of the pinion against the rack may move at least a part of the plunger rod along the longitudinal axis of the barrel.Type: ApplicationFiled: December 24, 2024Publication date: April 24, 2025Applicant: Regeneron Pharmaceuticals, Inc.Inventors: Sibgat ULLA, Danielle LAIACONA, Ross KENYON, Trevor LANGLEY, Bryan GRYGUS, Eric HOUDE, Jeremy McNAMARA, Kathryn VENUTO
-
Patent number: 12282004Abstract: A modular test fixture is configured to quickly support test samples of different configurations for testing.Type: GrantFiled: September 16, 2020Date of Patent: April 22, 2025Assignee: Regeneron Pharmaceuticals, Inc.Inventors: Christopher Hunter, Ruchika Sharma, Wesley Mahunik
-
Patent number: 12280124Abstract: Described herein are protein-drug conjugates and compositions thereof that are useful, for example, for targeting glucagon-like peptide 1 receptor (GLP1R). In certain embodiments, provided are peptidomimetic payloads and linker-payloads and methods of making same. More specifically, GLP1 peptidomimetics, antibody-drug conjugates, and compositions which comprise anti-GLP1R antibodies and GLP1 peptidomimetic payloads and methods of treating GLP1R-associated conditions are provided.Type: GrantFiled: September 14, 2021Date of Patent: April 22, 2025Assignee: REGENERON PHARMACEUTICALS, INC.Inventors: Amy Han, Haruka Okamoto, William Olson
-
Patent number: 12281173Abstract: The present invention provides methods for treating patients suffering from hypercholesterolemia, wherein the patient is non-responsive to, inadequately controlled by, or intolerant to treatment with a standard lipid modifying therapy. The methods of the invention provide for lowering at least one lipid parameter in the patient by administering a therapeutically effective amount of an antibody or antigen-binding fragment thereof that specifically binds to proprotein convertase subtilisin/kexin type 9 (PCSK9) in combination with a therapeutically effective amount of an antibody that specifically binds to angiopoietin-like protein 3 (ANGPTL3).Type: GrantFiled: March 3, 2020Date of Patent: April 22, 2025Assignee: Regeneron Pharmaceuticals, Inc.Inventors: Viktoria Gusarova, Jesper Gromada, Andrew J. Murphy
-
Patent number: 12274865Abstract: Disclosed herein are devices and methods for delivering a predetermined volume of a drug substance or other product including a fluid. An exemplary device may include a body configured to receive a drug substance therein, and a plunger rod disposed at least partially inside the body to distally move a stopper in the body. The device may include a component configured to regulate distal movement of the plunger rod in a priming step and in a subsequent delivery step, so that the device may be accurately primed and may accurately dispense a predetermined volume of a drug substance.Type: GrantFiled: August 1, 2022Date of Patent: April 15, 2025Assignee: Regeneron Pharmaceuticals, Inc.Inventors: Trevor Langley, Justin Bechstein, Jeremy Odegard, Sibgat Ulla, Daniel Halbig, Bryan Grygus, Prithvi Singh, Andrew Dumont, David Nett, Tasha Gillum, Ryan Ainsworth
-
Patent number: 12274747Abstract: The present invention provides compositions and methods for treating cancer and inhibiting cytokine release syndrome (CRS). The methods of the present invention comprise administering to a subject in need thereof a therapeutically effective amount of a CD40 antagonist or a CAR-T cell expressing a CD40 antagonist in combination with a therapeutically effective amount of a CD3 multispecific antigen binding molecule.Type: GrantFiled: January 28, 2022Date of Patent: April 15, 2025Assignee: Regeneron Pharmaceuticals, Inc.Inventors: Kara Olson, Olga Sineshchekova, Eric Smith, Chia-Yang Lin
-
Patent number: 12275792Abstract: The present invention provides antibodies and antigen-binding fragments of antibodies that bind to leptin receptor (LEPR), and methods of using the same. According to certain embodiments, the invention includes antibodies and antigen-binding fragments of antibodies that bind LEPR and activate LEPR signaling. In other embodiments, the invention includes antibodies and antigen-binding fragments of antibodies that bind to LEPR and enhance sensitization of LEPR to an antigen. In certain embodiments, the invention includes antibodies and antigen-binding fragments of antibodies that bind LEPR in the presence and absence of leptin. In certain embodiments, the invention includes antibodies and antigen-binding fragments of antibodies that induce signaling in cells expressing LEPR mutants that otherwise exhibit defective or impaired signaling in the presence of leptin.Type: GrantFiled: November 30, 2021Date of Patent: April 15, 2025Assignee: REGENERON PHARMACEUTICALS, INC.Inventors: Jesper Gromada, Panayiotis Stevis, Judith Altarejos
-
Patent number: 12268730Abstract: The present invention provides methods for treating angiogenic eye disorders by sequentially administering multiple doses of a VEGF antagonist to a patient. The methods of the present invention include the administration of multiple doses of a VEGF antagonist to a patient at a frequency of once every 8 or more weeks. The methods of the present invention are useful for the treatment of angiogenic eye disorders such as age related macular degeneration, diabetic retinopathy, diabetic macular edema, central retinal vein occlusion, branch retinal vein occlusion, and corneal neovascularization.Type: GrantFiled: October 27, 2023Date of Patent: April 8, 2025Assignee: Regeneron Pharmaceuticals, Inc.Inventor: George D. Yancopoulos
-
Patent number: 12269889Abstract: The present invention provides antibodies that bind to the human glucagon receptor, designated GCGR and methods of using same. According to certain embodiments of the invention, the antibodies are fully human antibodies that bind to human GCGR. The antibodies of the invention are useful for lowering blood glucose levels and blood ketone levels and are also useful for the treatment of diseases and disorders associated with one or more GCGR biological activities, including the treatment of diabetes, diabetic ketoacidosis and long-term complications associated with diabetes, or other metabolic disorders characterized in part by elevated blood glucose levels.Type: GrantFiled: October 11, 2022Date of Patent: April 8, 2025Assignee: REGENERON PHARMACEUTICALS, INC.Inventors: Haruka Okamoto, Mark Sleeman, Joyce Harp
-
Patent number: 12269897Abstract: An human antibody or antigen-binding fragment of a human antibody that specifically binds and inhibits human proprotein convertase subtilisin/kexin type 9 (hPCSK9) characterized by the ability to reduce serum LDL cholesterol by 40-80% over a 24, 60 or 90 day period relative to predose levels, with little or no reduction in serum HDL cholesterol and/or with little or no measurable effect on liver function, as determined by ALT and AST measurements.Type: GrantFiled: April 5, 2023Date of Patent: April 8, 2025Assignee: REGENERON PHARMACEUTICALS, INC.Inventors: Mark W. Sleeman, Joel H. Martin, Tammy T. Huang, Douglas MacDonald
-
Publication number: 20250109194Abstract: Antigen binding molecules (ABMs) comprising Fab domains in non-native configurations, ABM conjugates comprising the ABMs and cytotoxic or cytostatic agents, pharmaceutical compositions containing the ABMs and ABM conjugates, methods of using the ABMs, ABM conjugates and pharmaceutical compositions for treating cancer, nucleic acids encoding the ABMs, cells engineered to express the ABMs, and methods of producing ABMs.Type: ApplicationFiled: December 11, 2024Publication date: April 3, 2025Applicant: Regeneron Pharmaceuticals, Inc.Inventors: Tong ZHANG, Samuel DAVIS, Chia-Yang LIN, Eric SMITH, Erica PYLES, Michael ROSCONI, Nina LIU, Supriya PATEL, Andrew J. MURPHY
-
Publication number: 20250109207Abstract: The present disclosure relates to chimeric heavy chain constant domains having reduced effector function. Also disclosed are recombinant polypeptides comprising such chimeric heavy chain constant domains, including antibodies such as multispecific antibodies, fusion proteins, and other recombinant proteins. Nucleic acids encoding such recombinant polypeptides are also disclosed, as well as cells expressing such recombinant polypeptides and pharmaceutical compositions comprising such recombinant polypeptides.Type: ApplicationFiled: April 20, 2023Publication date: April 3, 2025Applicant: Regeneron Pharmaceuticals, Inc.Inventors: Naga Suhasini AVVARU, Samuel DAVIS, Chia-Yang LIN, Yang SHEN
-
Publication number: 20250108173Abstract: A drug delivery device is disclosed, wherein the device comprises a housing; a cap located at a proximal end of the housing, the cap including a first pair of deflectable arms and a second pair of deflectable arms; a product vessel arranged in the housing, and a needle coupled to a distal end of the product vessel; a plunger rod for dispensing a product from the product vessel, wherein the plunger rod is slidably received within the cap and partially disposed inside the product vessel; and a needle cover at least partially disposed in the housing, wherein the first pair of deflectable arms are configured to deflect radially inwards towards the plunger rod and the second pair of deflectable arms are configured to radially outwards away from the plunger rod.Type: ApplicationFiled: October 1, 2024Publication date: April 3, 2025Applicant: Regeneron Pharmaceuticals, Inc.Inventors: Trevor LANGLEY, Bryan C. GRYGUS, Danielle Laiacona, Noah Bennett, Alexander Roumanidakis, Jessica Miklinski, Maya Vanderhorst, Parker Valdez
-
Patent number: 12264343Abstract: The present disclosure provides improved genome editing compositions and methods for editing a TCR? gene.Type: GrantFiled: February 24, 2023Date of Patent: April 1, 2025Assignee: REGENERON PHARMACEUTICALS, INC.Inventors: Jordan Jarjour, Mark Pogson
-
Patent number: 12264366Abstract: The present disclosure provides methods of reducing cardiovascular risk by administration of a PCSK9 inhibitor to patients having a genetic profile associated with response to PCSK9 inhibitor therapy.Type: GrantFiled: May 16, 2020Date of Patent: April 1, 2025Assignee: Regeneron Pharmaceuticals, Inc.Inventors: Amy Damask, Charles Paulding, Aris Baras, Goncalo Abecasis
-
Publication number: 20250101125Abstract: Disclosed herein are methods for isolating antibody-producing cells that express antibody molecules specific for an interface between a target peptide and an MHC molecule. The methods disclosed herein utilize a blocking reagent when sorting cells such as splenocytes which permits enrichment of cells expressing rare antibody molecules that specifically recognize an MHC-peptide interface.Type: ApplicationFiled: June 28, 2024Publication date: March 27, 2025Applicant: Regeneron Pharmaceuticals, Inc.Inventors: Wen-Yi LEE, David SUH, Gang CHEN
-
Patent number: 12256720Abstract: Non-human animals comprising a human or humanized DPP4 nucleic acid sequence are provided. Non-human animals that comprise a replacement of the endogenous Dpp4 gene with a human or humanized DPP4 gene, or non-human animals comprising a human or humanized DPP4 gene in addition to the endogenous Dpp4 gene are described. Non-human animals comprising a human or humanized DPP4 gene under control of human or non-human DPP4 regulatory elements is also provided, including non-human animals that have a replacement of non-human Dpp4-encoding sequence with human DPP4-encoding sequence at an endogenous non-human Dpp4 locus. Non-human animals comprising human or humanized DPP4 gene sequences, wherein the non-human animals are rodents, e.g., mice or rats, are provided. Methods for making and using the non-human animals are described.Type: GrantFiled: April 21, 2021Date of Patent: March 25, 2025Assignee: Regeneron Pharmaceuticals, Inc.Inventors: Christos Kyratsous, Alexander Mujica
-
Patent number: 12259355Abstract: Microchip Capillary Electrophoresis (MCE) assays and reagents to assess purity and to identify impurities in protein drug product samples are provided. Methods for analyzing analytes in a protein drug sample are provided.Type: GrantFiled: July 6, 2021Date of Patent: March 25, 2025Assignee: Regeneron Pharmaceuticals, Inc.Inventors: Timothy Riehlman, Gabriel Carreau, Jeffrey Schneiderheinze, Nicole M. Nall
-
Patent number: 12259373Abstract: Disclosed are methods for improving compound detection and characterization. Methods for characterizing a sample are disclosed. The methods can include providing a sample to a liquid chromatography system capable of sample separation to generate sample components; analyzing sample components by multiplexed targeted selected ion monitoring (SIM) to generate an inclusion list; and performing iterative mass spectral data-dependent acquisition (DDA) from the inclusion list, to identify individual sample components thereby characterizing the sample. In one example, multiplexed targeted SIMs and iterative MS2 DDA acquisition is used to increase robust compound identification for cell culture medium analysis.Type: GrantFiled: March 20, 2024Date of Patent: March 25, 2025Assignee: Regeneron Pharmaceuticals, Inc.Inventors: Jikang Wu, Hongxia Wang, Haibo Qiu, Ning Li